✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
GWP42003-P is an investigational drug.
There have been 30 clinical trials for GWP42003-P. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2020.
The most common disease conditions in clinical trials are Syndrome, Epilepsy, and Seizures. The leading clinical trial sponsors are GW Research Ltd, University of Utah, and State of Georgia.
There is one US patent protecting this investigational drug and five international patents.
Recent Clinical Trials for GWP42003-P
|Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy||National Cancer Institute (NCI)||Phase 2|
|Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy||Mayo Clinic||Phase 2|
|Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures||Jazz Pharmaceuticals||Phase 3|
Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GWP42003-P||See Plans and Pricing||Pharmaceutical formulations||GW Pharma Limited (Cambridge, GB)||See Plans and Pricing|
|GWP42003-P||See Plans and Pricing||Compositions and methods for treating chronic inflammation and inflammatory diseases||Infirst Healthcare Limited (London, GB)||See Plans and Pricing|
|GWP42003-P||See Plans and Pricing||Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols||KANNALIFE SCIENCES, INC. (Huntington, NY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GWP42003-P||Australia||AU2002231970||2021-02-14||See Plans and Pricing|
|GWP42003-P||Canada||CA2438097||2021-02-14||See Plans and Pricing|
|GWP42003-P||Canada||CA2533400||2021-02-14||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|